Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WCLC 2023 | Assessing the role of consolidation therapy for EGFR-mutant NSCLC

Amin Nassar, MD, Yale Cancer Centre, New Haven, CT, shares the key takeaways of a retrospective analysis of consolidation therapy for patients with stage III unresectable EGFR-mutant non-small cell lung cancer (NSCLC). The study investigated clinical outcomes of patients treated with consolidation durvalumab, consolidation osimertinib, and patients who received neither. Progression-free survival (PFS) was significantly longer in patients who received osimertinib. No difference in overall survival (OS) was observed, however this may be attributed to the limited follow-up time. The rate of treatment-related adverse events was similar between treatment groups. Nevertheless, the rates of pneumonitis were lower in the osimertinib cohort. The safety profile was consistent and no new signals were observed. Dr Nassar concludes that patients with unresectable stage III EGFR-mutant NSCLC may have a benefit in PFS with consolidation osimertinib, but a longer follow-up will be required to generate OS data. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.